close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

9.600 -0.170 (-1.74%)
Streaming Delayed Price Updated: 10:31 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
From NeoGenomics, Inc.
Via Business Wire
NEO Q3 Deep Dive: Clinical Volume Gains and New Product Launches Shape Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 11.9% year on year to $187.8 million. The company... 
Via StockStory
Earnings Scheduled For October 28, 2025
 
Via Benzinga
4 Analysts Assess NeoGenomics: What You Need To Know
 
Via Benzinga
NeoGenomics (NEO) Q3 2025 Earnings Call Transcript
NeoGenomics (NEO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
Why NeoGenomics (NEO) Stock Is Trading Up Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations. 
Via StockStory
Topics World Trade
NeoGenomics Inc (NASDAQ:NEO) Surpasses Q3 Revenue Estimates as Clinical Testing Drives Growth
NeoGenomics Q3 2025 earnings beat revenue estimates with 11.9% growth. Clinical test volume surged 15%, driving a 5.4% pre-market stock rally. 
Via Chartmill
Topics Earnings
NeoGenomics’s (NASDAQ:NEO) Q3 Sales Top Estimates, Stock Soars
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 11.9% year on year to $187.8 million. The company expects the full... 
Via StockStory
NeoGenomics Reports Third Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics (NEO) Reports Earnings Tomorrow: What To Expect
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results this Tuesday before market open. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
3 Healthcare Stocks Walking a Fine Line
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
3 Unprofitable Stocks with Open Questions
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Federal Reserve Signals Further Rate Cuts Amidst Worsening Labor Market and Divided Opinions
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025
From NeoGenomics, Inc.
Via Business Wire
3 Russell 2000 Stocks We Approach with Caution
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations. 
Via StockStory
Topics World Trade
3 Cash-Burning Stocks We’re Skeptical Of
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
Via StockStory
NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026
Adhishthana.com analysis shows NeoGenomics has chosen the blue pill, consolidation likely to last until August 2026. 
Via Benzinga
Anchored at 4%: Why the Steady 10-Year Treasury Yield is Key to Unlocking the Fed's Stimulus Power
The U.S. financial markets are currently at a critical juncture, with the stability of the 10-year Treasury yield hovering steadfastly around the 4% mark. This apparent calm in long-term borrowing... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
1 Safe-and-Steady Stock Worth Your Attention and 2 We Ignore
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Why NeoGenomics (NEO) Shares Are Falling Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 5.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early... 
Via StockStory
Topics Intellectual Property Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
Bond Yields Tumble as Investors Brace for Aggressive Fed Rate Cuts
U.S. Treasury yields have recently experienced a significant decline, with the benchmark 10-year Treasury note falling to its lowest levels since April 2025. This sharp dip in yields reflects a... 
Via MarketMinute
Topics Bonds Economy Supply Chain
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
From Pomerantz LLP
Via GlobeNewswire
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
1 Surging Stock with Exciting Potential and 2 That Underwhelm
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
Why Is NeoGenomics (NEO) Stock Soaring Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 22.5% in the morning session after a court ruled in the company's favor in a patent infringement lawsuit against Natera. 
Via StockStory
Topics Economy Intellectual Property Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today